TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00179205
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo (1 can) administered during the hemodialysis procedure; every other day, 3 days per week, for 3 months; each can contains a total of 60 calories: 0 calories from protein, 60 calories from carbohydrates, and 0 calories from fat.
Study: NCT00546455
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules/day
Study: NCT00203060
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, once daily, 58 weeks
Study: NCT02719834
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (regular strength) will be provided in two capsules: 325 mg, take two capsules 3 times/day for 28 days (1,950 maximum daily dose). Capsules will be labeled to maintain blinding.
Study: NCT01986361
Drug: flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single flurbiprofen 8.75 mg lozenge which also contains 1 mg of menthol in its vehicle base for flavour and taste purposes (blinding). Lozenge is sucked until dissolved, and not chewed, bit or swallowed.
Study: NCT01986361
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single placebo lozenge which also contains 1 mg of menthol in its vehicle base for flavour and taste purposes (blinding). Lozenge is sucked until dissolved, and not chewed, bit or swallowed.
Study: NCT00202774
Drug: (capecitabine, oxaliplatin, 5-fluorouracil)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02411175
Drug: 20% ethanol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01293201
Drug: STAHIST
Normalized name: Stahist
Approvals — FDA: no, EMA: no, PMDA: no
Description: STAHIST dosed one tablet, BID
Study: NCT01293201
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo identical in appearance to IMP, dosed one tablet BID
Study: NCT00861315
Drug: Nebulized amikacin
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin is nebulized at a dose of 60 mg/Kg (6 first patients of the arm), 80 mg/Kg (6 subsequent patients) or 100 mg/Kg (last 6 patients of the arm)
Study: NCT00861315
Drug: Intravenous amikacin
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg/Kg amikacin are administred intravenousely once a day during three days.
Study: NCT00861315
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline is administered intravenousely once a day during three days
Study: NCT00966745
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01962376
Drug: Oxaliplatin;Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.
Study: NCT03837015
Drug: Estring Vaginal Ring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol vaginal ring, containing 2mg estradiol designed for slow release over 30 days
Study: NCT03535532
Drug: standard medical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard medical treatment: detailed medicine strategy chosen for each patient will be associated with their own conditions based on current guidance recommendations.
Study: NCT01844973
Drug: M518101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proper quantity twice a day
Study: NCT01844973
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proper quantity twice a day
Study: NCT00096278
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00096278
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04631874
Drug: CDFF0318, Champix
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDFF0318: Varenicline salt changed Champix: Varenicline tartrate
Study: NCT00674765
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day
Study: NCT00604396
Drug: insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01901861
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is given before meal ingestion
Study: NCT04421456
Drug: GWP42003-P
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral solution containing 100 milligrams per milliliter (mg/mL) cannabidiol (CBD) dissolved in the excipients sesame oil and anhydrous ethanol (10% v/v), with sweetener (sucralose), and strawberry flavoring
Study: NCT04421456
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral solution containing the excipients sesame oil and anhydrous ethanol, with added β-carotene, sweetener (sucralose), and strawberry flavoring
Study: NCT02054442
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01472965
Drug: ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 70% ethanol catheter lock therapy
Study: NCT03522688
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group was given normal saline by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour
Study: NCT00628095
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: no active ingredient
Study: NCT01897610
Drug: Immuncell-LC
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous dripping of 200ml(10\^9\~2x10\^10 lymphocytes/60kg adult) for 1 hour
Study: NCT04079530
Drug: K-877 IR 0.2 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-877 IR 0.1 mg tablet
Study: NCT04079530
Drug: K-877 CR 0.4 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-877 CR 0.4 mg tablet
Study: NCT04079530
Drug: K-877 CR 0.8 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two K-877 CR 0.4 mg tablet
Study: NCT02555124
Drug: JNJ-42847922, 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive single oral dose of 40 mg of JNJ-42847922 on Day 1, fasted condition.
Study: NCT02555124
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo on Day 1, fasted condition in Cohort A, Cohort B and Cohort C.
Study: NCT03334318
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo tablets administered in the PERL Clinical Trial
Study: NCT01274000
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02746783
Drug: Double dose of MUTAGRIP® influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive either a single or double doses of MUTAGRIP® containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012. The double dose regimen will be administered at the same time.
Study: NCT02818621
Drug: Group Dex (dexmedetomidine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mcg/kg loading dose followed by 0.5mcg/kg/hr infusion of dexmedetomidine which was administered at induction of anesthesia through skin closure
Study: NCT02348359
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03422159
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic Acid 1.5g IV piggyback every 6 hours for 4 days (or discharge from ICU if prior to 4 days).
Study: NCT03422159
Drug: Thiamine
Normalized name: Thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiamine 200mg IV piggyback every 12 hours for 4 days (or discharge from ICU if prior to 4 days).
Study: NCT03422159
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone 50mg IV push every 6 hours for 4 days (or discharge from ICU if prior to 4 days).
Study: NCT02669914
Drug: MEDI4736
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02499497
Drug: LY2452473
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.
Study: NCT02499497
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will receive pills containing no active drug.
Study: NCT01329588
Drug: Monthly antibiotic
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Azithromycin 1g per os once at months 1, 4 and 7 Ciprofloxacin 500 mg per os once at months 2, 3, 5, 6, 8 and 9
Study: NCT01329588
Drug: Monthly placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin placebo (sugar pill) per os once at months 1, 4 and 7 Ciprofloxacin placebo (sugar pill) per os once at months 2, 3, 5, 6, 8 and 9
Study: NCT00047229
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03515629
Drug: REGN2810/ipi
Approvals — FDA: no, EMA: no, PMDA: no
Description: REGN2810 plus ipilimumab
Study: NCT03515629
Drug: REGN2810/chemo/ipi
Approvals — FDA: no, EMA: no, PMDA: no
Description: REGN2810 plus chemotherapy plus Ipilimumab
Study: NCT03329248
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Study: NCT03329248
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Study: NCT03329248
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione
Study: NCT03329248
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
Study: NCT00851773
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg once weekly, s.c. injection
Study: NCT00851773
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg once weekly, s.c. injection
Study: NCT00851773
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg once weekly, s.c. injection
Study: NCT00851773
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg once weekly for 1 week, 0.8 mg once weekly for 7 weeks, s.c. injection
Study: NCT00851773
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg once weekly for 1 week, 0.8 mg once weekly for 1 week, followed by 1.2 mg once weekly injections for 6 weeks, s.c. injection
Study: NCT02538692
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is the same as Tong-Xie-Yao-Fang in appearance.
Study: NCT01053520
Drug: ABT-263
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1: Single (oral) dose of 25 mg of Formulation A Period 2: Single (oral) dose of 25 mg of Formulation B1 Period 3: Single (oral) dose of 25 mg of Formulation B2
Study: NCT01053520
Drug: ABT-263
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1: Single (oral) dose of 25 mg of Formulation B1 Period 2: Single (oral) dose of 25 mg of Formulation B2 Period 3: Single (oral) dose of 25 mg of Formulation A
Study: NCT01053520
Drug: ABT-263
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1: Single (oral) dose of 25 mg of Formulation B2 Period 2: Single (oral) dose of 25 mg of Formulation A Period 3: Single (oral) dose of 25 mg of Formulation B1
Study: NCT00990067
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules identical to MDMA or duloxetine
Study: NCT00904839
Drug: BIBF 1120
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBF 1120 100 and 150 mg capsules
Study: NCT00904839
Drug: mFolfox
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard i.v chemotherapy
Study: NCT00904839
Drug: mFolfox 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV standard chemotherapy
Study: NCT03197194
Drug: acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one tablet of aspirin 300 mg
Study: NCT03197194
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo oral tablet which doesn't contain the active ingredient acetyl salicylic acid
Study: NCT03197194
Drug: placebo IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV saline solution (0.9 %):10 mL in a syringe administered over 1 minute, followed by 50 mL as an infusion over 1 hour
Study: NCT01364922
Drug: hydrocodone/acetaminophen extended release
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01364922
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04712032
Drug: ICG-guided bowel perfusion assessment
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ICG will be injected prior to anastomosis creation, to assess perfusion status of the bowel.
Study: NCT03967197
Drug: Saline spray
Normalized name: Saline Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiologic saline spray
Study: NCT01651273
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, Oral, 0 mg, Once daily, 28 days
Study: NCT02080182
Drug: placebo acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01985256
Drug: Toca FC
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02203513
Drug: LY2606368
Approvals — FDA: no, EMA: no, PMDA: no
Description: 105 mg/m\^2 intravenous (IV) once every 14 days of a 28 day cycle
Study: NCT01441596
Drug: Investigator's choice of treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive, at the investigator's discretion, the most appropriate medical treatment consisting of single agent or combination regimen approved for the treatment of metastatic breast cancer, and according to patient status and local guidelines.
Study: NCT00070213
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00070213
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00070213
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00070213
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01323790
Drug: NKTR-118
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg oral tablet once daily
Study: NCT02854605
Drug: Placebo to match GS-9674
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet(s) administered orally once daily
Study: NCT01323790
Drug: NKTR-118
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg oral tablet once daily
Study: NCT01323790
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to NKTR-118
Study: NCT02372318
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT00287677
Drug: HAART
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAART all over the trial
Study: NCT00003088
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: given IV
Study: NCT00003088
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: given IV
Study: NCT02944981
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose
Study: NCT04255407
Drug: Anti-inflammatory drug
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain before and after ACL reconstruction will be managed with common anti-inflammatory drugs (Paracetamol)
Study: NCT01440569
Drug: DRV
Normalized name: Urinal Male Drv RTLPC23201
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg (2 x 400 mg tablets) administered orally with food once daily
Study: NCT01440569
Drug: NRTIs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 2 nucleoside analogue reverse transcriptase inhibitors (NRTIs) selected by the investigator after resistance testing at screening and administered according to prescribing information. NRTIs may include emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), zidovudine+FTC/TDF, abacavir (ABC)+TDF, ABC+FTC/TDF, ABC+lamivudine (3TC), or didanosine (DDI)+FTC.
Study: NCT01490697
Drug: Placebo-matching d-Cycloserine (DCS)
Normalized name: D-(+)-cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo-matching DCS capsules
Study: NCT01270906
Drug: CHIR-258 (TKI258)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00923169
Drug: Anti-Transforming Growth Factor-beta (GC 1008)
Normalized name: transforming growth factor beta 2
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01636726
Drug: Inhaled LABA use
Approvals — FDA: no, EMA: no, PMDA: no
Description: LABA prescription during the study period between Jan 1, 2002 and Dec 31, 2009
Study: NCT00488267
Drug: ThermoProfen™ (Matrix Transdermal Ketoprofen/CHADD™ System)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal patch applied to the knee for 12 hours daily.
Study: NCT00488267
Drug: Placebo Matrix/CHADD Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal patch applied to the knee for 12 hours daily.
Study: NCT00488267
Drug: Ketoprofen matrix/placebo CHADD Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal knee applied to the knee for 12 hours daily.
Study: NCT03953079
Drug: Drug: GB-102
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of GB-102
Study: NCT01966679
Drug: AZD7325
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01966679
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00379808
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 lactose-containing capsule daily for 1 month
Study: NCT01432561
Drug: Cysteamine bitartrate
Normalized name: Cysteamine Bitartrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg total, single dose taken orally on visits 2, 3 \& 4 which must occur within a 14 day period.
Study: NCT00129181
Drug: carbidopa/levodopa
Normalized name: CARBIDOPA/LEVODOPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately 120 Parkinson's disease subjects will be randomized to receive either carbidopa/levodopa, cabergoline or no treatment during a twelve week period. Subjects will undergo SPECT imaging with DATscan at screening and after 12 weeks. After twelve weeks carbidopa/levodopa and cabergoline treatment will be withdrawn and all subjects will undergo SPECT imaging with DATscan after 8 weeks (20 weeks after baseline).
Study: NCT02214095
Drug: glucosamine sulphate
Normalized name: Glucosamine Sulfate 750 MG Oral Capsule [GLUCOSAMINE SULPHATE]
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: group I (G1) patients received 500 mg glucosamine sulphate capsules (Glucosamine Compound) , three times daily for 3 months following initial cause related therapy. Group II patients were given placebo capsules( Lactose) for the same period following initial cause related therapy
Study: NCT02214095
Drug: lactose capsules
Normalized name: lactose Oral Capsule
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00546325
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets. Once daily before breakfast
Study: NCT02860117
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo continuous infusion (0,2 ml/kg/h)
Study: NCT01813513
Drug: IDX719
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg tablet for oral administration
Study: NCT01659658
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide tablets
Study: NCT02291549
Drug: S8 Sinus Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
Study: NCT00919815
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: prednisolone 40mg daily then reducing regimen over 24 weeks
Study: NCT01489683
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml of normal saline was instilled to larynx and trachea before endotracheal intubation
Study: NCT01763307
Drug: RECONVAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01763307
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01780428
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00515892
Drug: Immunotoxin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02312258
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixazomib placebo-matching capsules.
Study: NCT00004401
Drug: botulism immune globulin
Normalized name: botulism immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02570672
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will randomized to placebo will receive placebo
Study: NCT02852122
Drug: C-11 choline
Normalized name: choline C-11
DrugBank: Choline C-11 (DB09563)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is an uncontrolled, open-labeled, non-randomized, prospective study. The study duration is expected to be completed in a period of 2 years. Up to 54 patients with primary prostate cancer and stratified as high risk group (PSA \> 20 ng/mL, or Gleason score 8-10, or clinical stage \>T2c) would be included.
Study: NCT02556437
Drug: Subcuvia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human immunoglobulin 16% for subcutaneous injection
Study: NCT02287350
Drug: diclofenac potassium oral solution
Normalized name: diclofenac potassium Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of diclofenac potassium oral solution, taken by mouth, as needed for mild to moderate acute pain.
Study: NCT01303120
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient controlled analgesia with morphine